{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Hormone-receptor-positive+Breast+Cancer&page=5", "query": { "condition": "Hormone-receptor-positive Breast Cancer", "page": 5 }, "page_size": 10 }, "pagination": { "page": 5, "page_size": 10, "total_count": 411, "total_pages": 42, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Hormone-receptor-positive+Breast+Cancer&page=6&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Hormone-receptor-positive+Breast+Cancer&page=4&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-14T09:44:24.727Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT02309177", "title": "Safety Study of Nivolumab With Nab-Paclitaxel Plus or Minus Gemcitabine in Pancreatic Cancer, Nab-Paclitaxel / Carboplatin in Stage IIIB/IV Non-Small Cell Lung Cancer or Nab-Paclitaxel in Recurrent Metastatic Breast Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Breast Neoplasms", "Pancreatic Neoplasms" ], "interventions": [ { "name": "nab-Paclitaxel", "type": "DRUG" }, { "name": "Nivolumab", "type": "DRUG" }, { "name": "Gemcitabine", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Celgene", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 114, "start_date": "2015-01-12", "completion_date": "2018-09-12", "has_results": false, "last_update_posted_date": "2019-05-31", "last_synced_at": "2026-10-14T09:44:24.727Z", "location_count": 15, "location_summary": "Sacramento, California • Santa Monica, California • New Haven, Connecticut + 11 more", "locations": [ { "city": "Sacramento", "state": "California" }, { "city": "Santa Monica", "state": "California" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Tampa", "state": "Florida" }, { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT02309177" }, { "nct_id": "NCT00661531", "title": "Estrogen in Postmenopausal Women With ER Positive Metastatic Breast Cancer After Failure of Sequential Endocrine Therapy", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Breast Cancer", "Cancer of the Breast", "Neoplasms, Breast" ], "interventions": [ { "name": "Estrace", "type": "DRUG" }, { "name": "Anastrozole", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Georgetown University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 11, "start_date": "2008-04", "completion_date": "2015-06", "has_results": true, "last_update_posted_date": "2017-04-12", "last_synced_at": "2026-10-14T09:44:24.727Z", "location_count": 3, "location_summary": "Washington D.C., District of Columbia • Voorhees Township, New Jersey • Philadelphia, Pennsylvania", "locations": [ { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Voorhees Township", "state": "New Jersey" }, { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT00661531" }, { "nct_id": "NCT01491737", "title": "A Study of Pertuzumab in Combination With Trastuzumab Plus an Aromatase Inhibitor in Participants With Metastatic Human Epidermal Growth Factor Receptor 2 (HER2)-Positive and Hormone Receptor-Positive Advanced Breast Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Breast Cancer" ], "interventions": [ { "name": "Pertuzumab", "type": "DRUG" }, { "name": "Trastuzumab", "type": "DRUG" }, { "name": "Aromatase Inhibitor", "type": "DRUG" }, { "name": "Induction Chemotherapy", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Hoffmann-La Roche", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 258, "start_date": "2012-02-17", "completion_date": "2019-11-14", "has_results": true, "last_update_posted_date": "2020-10-28", "last_synced_at": "2026-10-14T09:44:24.727Z", "location_count": 21, "location_summary": "Birmingham, Alabama • Chandler, Arizona • Hot Springs, Arkansas + 17 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Chandler", "state": "Arizona" }, { "city": "Hot Springs", "state": "Arkansas" }, { "city": "Bakersfield", "state": "California" }, { "city": "Denver", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT01491737" }, { "nct_id": "NCT03393845", "title": "Study of Pembrolizumab Plus Fulvestrant in Hormone Receptor Positive, HER-2 Negative Advanced/Metastatic Breast Cancer Patients", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Breast Cancer" ], "interventions": [ { "name": "Pembrolizumab", "type": "DRUG" }, { "name": "Fulvestrant", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Nancy Chan, MD", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 47, "start_date": "2018-01-29", "completion_date": "2027-09-01", "has_results": false, "last_update_posted_date": "2026-01-02", "last_synced_at": "2026-10-14T09:44:24.727Z", "location_count": 5, "location_summary": "Lansing, Michigan • Omaha, Nebraska • New Brunswick, New Jersey + 2 more", "locations": [ { "city": "Lansing", "state": "Michigan" }, { "city": "Omaha", "state": "Nebraska" }, { "city": "New Brunswick", "state": "New Jersey" }, { "city": "New York", "state": "New York" }, { "city": "Madison", "state": "Wisconsin" } ], "official_url": "https://clinicaltrials.gov/study/NCT03393845" }, { "nct_id": "NCT00379197", "title": "Phase II of Naltrexone in Hormone-Refractory Metastatic Breast Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Breast Cancer" ], "interventions": [ { "name": "naltrexone", "type": "DRUG" }, { "name": "PET scan", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "PROCEDURE" ], "sponsor": "Masonic Cancer Center, University of Minnesota", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 13, "start_date": "2006-07", "completion_date": "2013-05", "has_results": true, "last_update_posted_date": "2017-12-28", "last_synced_at": "2026-10-14T09:44:24.727Z", "location_count": 1, "location_summary": "Minneapolis, Minnesota", "locations": [ { "city": "Minneapolis", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT00379197" }, { "nct_id": "NCT07020117", "title": "A Study of [225Ac]Ac-AKY-1189 in Patients With Solid Tumors", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Urothelial Carcinoma Bladder", "Triple Negative Breast Cancer (TNBC)", "Hormone Receptor Positive Breast Adenocarcinoma", "Non Small Cell Lung Cancer", "Cervical Adenocarcinoma", "Colorectal Adenocarcinoma", "Head and Neck Cancer" ], "interventions": [ { "name": "[225Ac]Ac-AKY-1189 (therapeutic)", "type": "DRUG" }, { "name": "[64Cu]Cu-AKY-1189 (imaging)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Aktis Oncology, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 150, "start_date": "2025-08-22", "completion_date": "2032-06", "has_results": false, "last_update_posted_date": "2026-09-17", "last_synced_at": "2026-10-14T09:44:24.727Z", "location_count": 14, "location_summary": "Duarte, California • Irvine, California • Miami, Florida + 10 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Irvine", "state": "California" }, { "city": "Miami", "state": "Florida" }, { "city": "Orlando", "state": "Florida" }, { "city": "Tampa", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT07020117" }, { "nct_id": "NCT04352777", "title": "Impact of Endocrine Therapy and Abemaciclib on Host and Tumor Immune Cell Repertoire/Function in Advanced ER+/HER2- Breast Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Metastatic Breast Cancer", "Locally Advanced Breast Cancer", "Hormone Receptor Positive Tumor" ], "interventions": [ { "name": "Abemaciclib", "type": "DRUG" }, { "name": "Fulvestrant", "type": "DRUG" }, { "name": "Aromatase Inhibitors", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Duke University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 18, "start_date": "2020-09-14", "completion_date": "2025-06-25", "has_results": false, "last_update_posted_date": "2025-07-20", "last_synced_at": "2026-10-14T09:44:24.727Z", "location_count": 1, "location_summary": "Durham, North Carolina", "locations": [ { "city": "Durham", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT04352777" }, { "nct_id": "NCT02088684", "title": "Study of LEE011 With Fulvestrant and BYL719 or BKM120 in Advanced Breast Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Breast Cancer" ], "interventions": [ { "name": "LEE011", "type": "DRUG" }, { "name": "BYL719", "type": "DRUG" }, { "name": "fulvestrant", "type": "DRUG" }, { "name": "BKM120", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 70, "start_date": "2014-05-19", "completion_date": "2018-04-17", "has_results": false, "last_update_posted_date": "2020-12-17", "last_synced_at": "2026-10-14T09:44:24.727Z", "location_count": 3, "location_summary": "Birmingham, Alabama • Boston, Massachusetts • Nashville, Tennessee", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT02088684" }, { "nct_id": "NCT04274933", "title": "A Study to Evaluate the Safety and Tolerability of Venetoclax Tablets in Combination With Capecitabine Tablets in Adult Participants With Hormone Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer Who Had Disease Progression During or After CDK4/6 Inhibitor Therapy", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Breast Cancer", "Cancer" ], "interventions": [ { "name": "Venetoclax", "type": "DRUG" }, { "name": "Capecitabine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AbbVie", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 4, "start_date": "2020-05-21", "completion_date": "2020-10-08", "has_results": false, "last_update_posted_date": "2020-10-29", "last_synced_at": "2026-10-14T09:44:24.727Z", "location_count": 11, "location_summary": "Joliet, Illinois • Boston, Massachusetts • Minneapolis, Minnesota + 7 more", "locations": [ { "city": "Joliet", "state": "Illinois" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Minneapolis", "state": "Minnesota" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT04274933" }, { "nct_id": "NCT00601900", "title": "Tamoxifen Citrate or Letrozole With or Without Bevacizumab in Treating Women With Stage IIIB or Stage IV Breast Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Invasive Breast Carcinoma", "Recurrent Breast Carcinoma", "Stage III Breast Cancer AJCC v6", "Stage IV Breast Cancer AJCC v6 and v7" ], "interventions": [ { "name": "Bevacizumab", "type": "BIOLOGICAL" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Letrozole", "type": "DRUG" }, { "name": "Questionnaire Administration", "type": "OTHER" }, { "name": "Tamoxifen Citrate", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "OTHER", "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 394, "start_date": "2008-09-24", "completion_date": "2024-01-29", "has_results": true, "last_update_posted_date": "2026-08-28", "last_synced_at": "2026-10-14T09:44:24.727Z", "location_count": 521, "location_summary": "Mobile, Alabama • Fort Smith, Arkansas • Antioch, California + 355 more", "locations": [ { "city": "Mobile", "state": "Alabama" }, { "city": "Fort Smith", "state": "Arkansas" }, { "city": "Antioch", "state": "California" }, { "city": "Berkeley", "state": "California" }, { "city": "Burbank", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00601900" } ] }